Zegalogue (dasiglucagon)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- dasiglucagon
- Company
- Zealand Pharma A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 30 May 2024
- EU approval
- Wed 24 Jul 2024
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006214
- ATC
- H04AA02
- Official record
- www.ema.europa.eu
Indication
Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Follow Zegalogue
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.